Publication:
Circulating levels of sclerostin are associated with cardiovascular mortality.

Loading...
Thumbnail Image

Date

2018-06-21

Authors

Novo-Rodríguez, Cristina
García-Fontana, Beatriz
Luna-Del Castillo, Juan De Dios
Andújar-Vera, Francisco
Ávila-Rubio, Verónica
García-Fontana, Cristina
Morales-Santana, Sonia
Rozas-Moreno, Pedro
Muñoz-Torres, Manuel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Cardiovascular diseases are a health problem throughout the world, especially in people with diabetes. The identification of cardiovascular disease biomarkers can improve risk stratification. Sclerostin is a modulator of the Wnt/β-catenin signalling pathway in different tissues, and it has recently been linked to vascular biology. The current study aimed to evaluate the relationship between circulating sclerostin levels and cardiovascular and non-cardiovascular mortality in individuals with and without type 2 diabetes. We followed up a cohort of 130 participants (mean age 56.8 years; 48.5% females; 75 with type 2 diabetes; 46 with prevalent cardiovascular disease) in which serum sclerostin levels were measured at the baseline. Time to death (both of cardiovascular and non-cardiovascular causes) was assessed to establish the relationship between sclerostin and mortality. We found that serum sclerostin concentrations were significantly higher in patients with prevalent cardiovascular disease (p

Description

MeSH Terms

Adaptor Proteins, Signal Transducing
Bone Morphogenetic Proteins
Cardiovascular Diseases
Cohort Studies
Diabetes Mellitus, Type 2
Female
Genetic Markers
Humans
Incidence
Kaplan-Meier Estimate
Logistic Models
Male
Middle Aged
Proportional Hazards Models
ROC Curve
Risk Factors

DeCS Terms

CIE Terms

Keywords

Citation